Aequum Pharmaceuticals

Aequum Pharmaceuticals is a clinical-stage biotechnology company focused on developing next-generation epigenetic therapies for the treatment of cancer. The company's primary focus is on the development of highly selective histone deacetylase (HDAC) inhibitors, specifically targeting the HDAC6 isoform to minimize off-target toxicities associated with pan-HDAC inhibitors. Their lead candidate, AQ-101, is being evaluated for its potential to treat hematological malignancies such as multiple myeloma and various solid tumors. Aequum aims to improve patient outcomes by combining its selective inhibitors with existing standard-of-care treatments to overcome resistance mechanisms. The company was founded by industry veterans with extensive experience in oncology drug discovery and development.